REGN1908/1909 prevented cat allergen-induced early asthmatic responses in an environmental exposure unit.
Cat allergy
Fel d 1
IgG monoclonal antibodies
allergic rhinitis
asthma
immune system diseases
passive immunotherapy
Journal
The Journal of allergy and clinical immunology
ISSN: 1097-6825
Titre abrégé: J Allergy Clin Immunol
Pays: United States
ID NLM: 1275002
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
15
03
2022
revised:
22
06
2022
accepted:
28
06
2022
pubmed:
8
8
2022
medline:
15
12
2022
entrez:
7
8
2022
Statut:
ppublish
Résumé
The dominant allergen in cat dander, Felis domesticus allergen 1 (Fel d 1), is a persistent trigger for allergic rhinitis and asthma symptoms. We evaluated the efficacy of Fel d 1 monoclonal antibodies (REGN1908/1909) in preventing cat allergen-induced early asthmatic responses (EARs) in cat-allergic patients with mild asthma. Patients were randomized to single-dose REGN1908/1909 600 mg (n = 29) or placebo (n = 27). The FEV NCT03838731. Single-dose REGN1908/1909 significantly prevented reductions in FEV Single-dose REGN1908/1909 significantly prevented reductions in FEV
Sections du résumé
BACKGROUND
The dominant allergen in cat dander, Felis domesticus allergen 1 (Fel d 1), is a persistent trigger for allergic rhinitis and asthma symptoms.
OBJECTIVE
We evaluated the efficacy of Fel d 1 monoclonal antibodies (REGN1908/1909) in preventing cat allergen-induced early asthmatic responses (EARs) in cat-allergic patients with mild asthma.
METHODS
Patients were randomized to single-dose REGN1908/1909 600 mg (n = 29) or placebo (n = 27). The FEV
TRIAL REGISTRATION
NCT03838731.
RESULTS
Single-dose REGN1908/1909 significantly prevented reductions in FEV
CONCLUSION
Single-dose REGN1908/1909 significantly prevented reductions in FEV
Identifiants
pubmed: 35934082
pii: S0091-6749(22)00984-8
doi: 10.1016/j.jaci.2022.06.025
pii:
doi:
Substances chimiques
Allergens
0
Banques de données
ClinicalTrials.gov
['NCT03838731']
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1437-1446Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.